Drug Patents owned by Array Biopharma Inc

1. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(6 years from now)

US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

CN102105459A ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

CN102105459B ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

CN102725283B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN102725283A ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN103896921A ARRAY BIOPHARMA INC Compound And Composition As A Protein Kinase Inhibitor
Aug, 2030

(7 years from now)

CN103896921B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN201202469P1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN303554B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2324008B1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2324008A1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2727918A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2727918B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Jul, 2031

(8 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Nov, 2032

(10 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor Aug, 2033

(10 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

2. Drug name - MEKTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(5 months from now)

US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(5 months from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(11 years from now)

CN1874768A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Jan, 2010

(12 years ago)

CN101633644B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN100519539C ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682A ARRAY BIOPHARMA INC N3 Alkylated Benzoimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101486682B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN1652776A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

CN101633645A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

CN101633644A ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor
Mar, 2023

(5 months from now)

CN104870427B ARRAY BIOPHARMA INC Preparation And Formulation Comprising An Mek Inhibitor Of Mek Inhibitors
Oct, 2033

(11 years from now)

CN104870427A ARRAY BIOPHARMA INC Preparation Of Formulation Comprising Mek Inhibitor
Oct, 2033

(11 years from now)

IN200403046P1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

IN248684B ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

IN201501287P2 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

IN334786B ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2130537B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2130536B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130536A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP3000810A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivative As Mek Inhibitor
Mar, 2023

(5 months from now)

EP2130537A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP2275102A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A4 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932A1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1482932B1 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Mar, 2023

(5 months from now)

EP1663210A1 ARRAY BIOPHARMA INC Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1663210B1 ARRAY BIOPHARMA INC Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1663210A4 ARRAY BIOPHARMA INC N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP2909182A1 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2909182B1 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2909182A4 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors Mar, 2023

(5 months from now)

US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal Mar, 2023

(5 months from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Jul, 2031

(8 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor Oct, 2033

(11 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor Oct, 2033

(11 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase; Treatment of melanoma with a braf mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.